Lasa Supergenerics Ltd

BSE Code : 540702
NSE Symbol : LASA
ISIN : INE670X01014
Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

Trade Now

Get Quotes

9.34 -0.50(-5.08%)

Open Price (₹)

9.93

Prev. Close (₹)

9.84

Volume (No’s)

218,891

Market Cap (₹)

49.30

Low Price (₹)

9.34

High Price (₹)

9.93 Chart

Technical Chart

Corparate Information

Financials

Corporate Action

Board Meetings

Start Date	End Date	Purpose
16-May-2025	28-May-2025	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Monday May 26 2025 inter alia; 1. To consider approve and take on records Audited financial results of the Company for the quarter and the year ended March 31 2025. 2. To discuss any other matter with the permission of the Chairperson. Pursuant to Regulation 29 and 30 of SEBI LODR Regulations, 2015 and in continuation to our update of intimation of board meeting dated 16.05.2025 We would like to inform you that baord meeting which was supposed to be held has been rescheduled to Wednesday , 28.05.2025, due to unforseen circumstances arising from heavy rains and water logging in Mumbai , making difficult for all directors to attend the Meeting (As Per BSE Announcement dated on 26.05.2025) Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 2.00 P.M. and concluded at 4.00 P.M. inter- alia have considered and approved the following: 1. The Audited Financial Results of the Company for the Quarter and financial Year ended March 31, 2025. 2. A copy of the statement of audited Financial Results, Cash Flow statement along with Audited Report submitted by the Statutory Auditors of the Company is attached herewith. (As Per BSE Announcement Dated on: 28/05/2025)
21-May-2025	20-May-2025	Pursuant to Regulation 30 of SEBI (LODR) Regulation 2015, we would like to inform you that the Board of Director in their Meeting held today which was commenced at 05.45 PM and Concluded at 06.15 PM Inter-alia have consider and approved the Following Appointment of Mr. Prathamesh Chalke as Additional Director (Executive Director) and Occupier of All Units of the Company. Further the aforesaid appointment shall be subject to approval of Members at the ensuing General Meeting /Postal Ballot of the Company.
05-Feb-2025	13-Feb-2025	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Thursday February 13 2025 inter alia; 1. To consider approve and take on records unaudited financial results of the Company along with the Limited Review Report for the quarter ended on December 31 2024. 2. To discuss any other matter with the permission of the Chairperson. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct the Trading Window shall continue to remain closed till 48 hours after the declaration of the unaudited financial results of the Company for the quarter ended December 31 2024. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 02.00 p.m. and concluded at 06.00 p.m. inter- alia have considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the quarter ended on December 31, 2024. 2. Limited Review Report from Statutory Auditor for the quarter ended on December 31, 2024. (As Per BSE Announcement Dated on: 13/02/2025)
22-Jan-2025	28-Jan-2025	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday January 28 2025 inter alia; 1. To consider approve finalize the issue of warrants and price of warrants convertible into equity shares / or equity shares to be issued on preferential basis in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (SEBI ICDR Regulations). 2. To consider approve finalize the proposal of fund raising by way of equity shares through rights issue in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 (SEBI ICDR Regulations) as permitted under applicable law subject to such regulatory/statutory approvals as may be required. 3. Any other matter with the permission of chair. Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 02.00 P.M. and concluded at 03.45 P.M. (As Per BSE Announcement Dated on: 28/01/2025)
20-Jan-2025	24-Jan-2025	Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015 notice is hereby given that Meeting of the Board of Directors of the Company is scheduled to be held on Friday, January 24, 2025, inter alia; 1. To consider, approve, finalize the issue of warrants and price of warrants convertible into equity shares / or equity shares to be issued on preferential basis in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). 2. To consider and approve draft notice of Extra -ordinary General Meeting. 3. Any other matter with the permission of chair. The Board Meeting to be held on 24/01/2025 Stands Cancelled. (As per BSE Announcement Dated on 22/01/2025)